AMD treatment Beovu became available in general hospitals with insurance coverage.

According to related industries, Novartis Korea's Beovu (Brolucizumab), which has been registered since April, passed drug committees of more than 30 medical institutions including Seoul National University Hospital and Sinchon Severance Hospital.

Wet AMD treatment Beovu, in combination with VEGF-A, is a mechanism that inhibits neovascular expression and retinal effusion, administered once a month for the first three months and once every three months. Beovu's efficacy has been demonstrated through two three-phase clinical trials HAWK and HARRIER studies compared to Eylea (Afribercept).

Clini